COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Protocol No
ALLIANCE-A221805-CIPN
Principal Investigator
Sakti Chakrabarti
Phase
II/III
Summary
This study is being done to answer the following question: Does duloxetine (either 30 mg or 60 mg) prevent numbness, tingling, and/or pain caused by your cancer treatment with oxaliplatin? We are doing this study because we want to find out if duloxetine can prevent Oxaliplatin-induced peripheral neuropathy (OIPN).
Description
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Stage II-III Colorectal Cancer
Participating Institutions
Drexel Town Center
Froedtert Menomonee Falls Hospital
Froedtert West Bend Hospital
Froedtert Hospital
Status
OPEN TO ACCRUAL